David Loew on Ipsen’s strong H1 2022 results
A message from CEO David Loew
Loading...
  • Media  arrow_down
    < Back
    • Press Releases
    • Media Statements
    • Media Library

    • Our 2023 Integrated Annual Report is live!

       Featured Image
  • Investorsarrow_down
      < Back
    • Investors
    • Investors
    • Financial Results
    • Annual Reports and Accounts
    • Corporate News
    • Financial Calendar
    • Investor Events
    • Shareholder Information
    • Share-Price Data
    • Regulated Information
    • Key Contacts
  • Partnering
  • Careersarrow_down
      < Back
    • Careers
    • Careers
    • Working at Ipsen
    • Culture
  • Loading...
  • English  EN     Français  FR     EN  arrow_down
    • EnglishEN
    • FrançaisFR
  • Global Global
    < Back
    • Global EN FR
    • Annual Report EN FR
    • Americas
    • Asia Pacific
    • Europe
    • United States
    • Brazil
    • Canada
    • Mexico
    • Australia
    • China
    • Singapore
    • South Korea
    • Japan
    • Belgium
    • Ukraine
    • UK
    • Germany
    • France
    • Nordics
    • Greece
    • Italy
    • Netherlands
    • Spain
    • Poland
    • Russia
    • Czech Republic
    • Switzerland
  • Home
  • Companyarrow_down
      < Back
    • Company
    • Company
    • Leadership
    • History
    • Fondation Ipsen
  • Sciencearrow_down
      < Back
    • Science
    • Oncology
    • Rare Disease
    • Neuroscience
    • Products
    • R&D
    • Pipeline
    • Clinical Trials
    • Lay Summaries
  • Sustainabilityarrow_down
      < Back
    • Sustainability
    • Sustainability
    • Environment
    • Patients
    • People
    • Governance
    • Our Standards
  • Patientsarrow_down
      < Back
    • Patients
    • Patients
    • Together for Oncology
    • Together for Rare Disease
    • Together for Neuroscience
    • Collaborate with us
  • Stories
  1. Home
  2. Stories
  3. Financial Results story

A message from CEO David Loew

Back

Post navigation

Previous
Next

A message from CEO David Loew

Hear what CEO David Loew has to say about our H1 2022 results.

A message from CEO David Loew

- 28 July 2022 - 1 mins read
A message from CEO David Loew

Hear what CEO David Loew has to say about our H1 2022 results.

Post navigation

Previous
Next

Share this on social media

  • Share on LinkedIn
  • Share on Twitter
  • Share on Facebook

Related stories

Strong growth and expanding pipeline in the first half of 2024 drive raised guidance
25 July 2024 1 mins read

Strong growth and expanding pipeline in the first half of 2024 drive raised guidance
Ipsen delivers FY 2023 results and anticipates four launches in 2024
08 February 2024 1 mins read

Ipsen delivers FY 2023 results and anticipates four launches in 2024
2023 year to date and third-quarter sales results
23 October 2023 1 mins read

2023 year to date and third-quarter sales results
A strong first half of 2023
27 July 2023 1 mins read

A strong first half of 2023
Ipsen FY/Q4 2022 results–A word from CEO David Loew
09 February 2023 1 mins read

Ipsen FY/Q4 2022 results–A word from CEO David Loew
A word from CEO David Loew
27 October 2022 1 mins read

A word from CEO David Loew

IPN price

€107.60

 €0.20 (0.19%)

  • Media
  • Investors
  • Partnering
  • Careers
  • Company
  • Sustainability
  • Patients
  • Stories
  • Annual Report
  • Contact us
Latest_Ipsen logo
LinkedIn Twitter Facebook Instagram Youtube
  • Terms and Conditions
  • Cookie Policy
  • Global Privacy Policy

Copyright © Ipsen Pharma. All rights reserved - 2024

You are now leaving the Ipsen group website. To continue, please click on Continue?